Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced it has closed the first tranche of a $20 million Series F financing, raising $11.7 million. The funding will be used to accelerate the growth in clinical adoption of Castle… Read More
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. If your are interested in reading our Privacy Policy you may read it here. Ok
